Arielle Elkrief: Excited to launch this pan Canadian phase 2 RCT of FMT and ICI in melanoma
Arielle Elkrief, Assistant Professor and Principal Scientist at University of Montreal, shared a post by Canadian Cancer Society on X, adding:
“Excited to launch this pan Canadian phase 2 RCT of FMT and ICI in melanoma with the The Canadian Cancer Trials Group, J. Lenehan, and Saman Maleki.
Thanks to the Canadian Cancer Society and Weston Family Foundation we will understand the mechanism of FMT to unlock the next generation of microbiome therapeutics.”
Quoting Canadian Cancer Society’s post:
“An estimated 11,300 Canadians are expected to be diagnosed with melanoma this year.
That’s why we are proud to be uniting with a team of 12 researchers and collaborators to lead one of the world’s largest randomized clinical trials using fecal microbiota transplantation to improve the effectiveness of treatments for advanced melanoma.
Discover how this promising treatment has already changed the lives of people facing cancer.
Visit the link below to learn more.”
Proceed to video attached to post.
Source: Arielle Elkrief/X and Canadian Cancer Society/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023